Recent Company News

• 07:05 AM ET Dec 19, 2025
  

  Evaxion provides update on EVX-B2, says Merck will not exercise its option for the vaccine candidate ($5.75, 0.00)

• 09:15 AM ET Dec 11, 2025
  

  Transcript Intelligence: Evaxion AS at Sidoti Year End Virtual Investor Conference ($6.37, 0.00)

• 12:48 PM ET Dec 09, 2025
  

  Sidoti Events, LLC's Year-End Virtual Investor Conference

• 08:26 AM ET Dec 08, 2025
  

  StreetAccount Summary - US Pre-market trading

• 03:01 PM ET Dec 06, 2025
  

  Evaxion AS announces new data for EVX-04 indicating it triggers strong specific T-cell responses and effectively prevents tumor growth in preclinical models ($5.25, 0.00)

• 08:02 AM ET Nov 20, 2025
  

  Evaxion announces data for lead antigens in cytomegalovirus vaccine program EVX-V1 ($4.88, 0.00)

• 07:59 AM ET Nov 12, 2025
  

  Evaxion announce 2026 financial calendar